NUESTRA HISTORIA

Hemos hecho grandes cosas en el pasado.
Hoy, estamos haciendo grandes cosas para el futuro.

Durante 125 años, nuestra empresa se ha guiado por la convicción de que son los grandes medicamentos los que cambian el mundo.

VER VIDEO: NUESTRA BÚSQUEDA PARA CURAR CONTINÚA

Enfrentar los retos de la atención médica del futuro requerirá más de la misma dedicación que nos ha convertido en un líder en la industria del cuidado de la salud. Este video, creado para celebrar nuestro 125 aniversario, destaca nuestros descubrimientos pasados y nuestras promesas para el futuro.

Desde 1891, nuestros investigadores han ayudado a encontrar nuevas formas de tratar y prevenir enfermedades, desde el descubrimiento de la vitamina B1, la primera vacuna contra el sarampión, los medicamentos para el catarro y antiácidos, hasta las primeras estatinas para tratar el colesterol alto. Nuestros científicos también han ayudado a desarrollar muchos productos para mejorar la salud animal, como las vacunas y los antibióticos. Hoy, como una importante compañía biofarmacéutica de investigación intensiva, nos enfocamos en hacer avances científicos importantes dentro de la hepatitis C, el VIH, la diabetes y la inmuno oncología.

Si bien nos sentimos orgullosos de nuestro pasado, nos entusiasma nuestro futuro. Nuestro objetivo es crear un futuro más saludable y brillante para las personas de todo el mundo.

El mantenimiento de este sitio es responsabilidad de Merck Sharp & Dohme Corp., una subsidiaria de Merck & Co., Inc., Kenilworth, NJ, USA.

Forward-Looking Statement

Forward-Looking Statement of MSD & Co., Inc., Kenilworth, NJ, USA

This website of MSD & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.